🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan NCT06099093Phase 42 sites📍 Boston📍 Boston Brigham and Women's Hospital · Tests: 18F-DCFPyl A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer NCT06609005Phase 1, Phase 222 sites📍 Scottsdale📍 Newport Beach📍 Orange Shenzhen Ionova Life Sciences Co., Ltd. · Tests: INV-9956 A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650Phase 3330 sites📍 Tucson📍 Irvine📍 Los Angeles Merck Sharp & Dohme LLC · Tests: Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer NCT04986423Phase 231 sites📍 Los Angeles📍 San Francisco📍 Whittier Zenith Epigenetics · Tests: ZEN003694, Enzalutamide Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial NCT06720532n/a1 site📍 Munich Hannah Schaefer · Tests: characterization of renal function., Handgrip strength test, Questionaires A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) NCT07723248Phase 312 sites📍 Coral Springs📍 Jeffersonville📍 Holland ORIC Pharmaceuticals · Tests: Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer NCT06236139Phase 1, Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Anti-STEAP1 CAR T-cells, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer NCT06600802NA5 sites📍 Clermont-Ferrand📍 La Tronche📍 Pierre-Bénite Centre Jean Perrin · Tests: Blood samples A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer NCT06457919Phase 1, Phase 212 sites📍 New Haven📍 Basking Ridge📍 Middletown Memorial Sloan Kettering Cancer Center · Tests: Tinengotinib, abiraterone acetate with prednisone, Enzalutamide A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan NCT07677267n/a1 site📍 East Hanover Novartis Pharmaceuticals ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer NCT03903835Phase 332 sites📍 Aalst📍 Antwerp📍 Bruges Karolinska Institutet · Tests: Enzalutamide Oral Capsule, Abiraterone Oral Tablet, Carboplatin, Cabazitaxel 60 mg Solution for Injection, Docetaxel In… A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer NCT07570979Phase 113 sites📍 Boston📍 Dallas📍 Melbourne Novartis Pharmaceuticals · Tests: INR731, Enzalutamide, Abiraterone, Androgen deprivation therapy (ADT) A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites📍 Duarte📍 Los Angeles📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-1607, Paclitaxel ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium NCT07414940Phase 1, Phase 21 site📍 London University College, London · Tests: Actinium (225Ac) rhPSMA-10.1 A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC NCT07567521Phase 1, Phase 22 sites📍 Taiyuan📍 Shanghai C Ray Therapeutics · Tests: Radiopharmaceuticals A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC NCT07226986Phase 1, Phase 225 sites📍 Los Angeles📍 Durham📍 El Paso Novartis Pharmaceuticals · Tests: AMO959, AAA617, Enzalutamide, Abiraterone Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer NCT07641049Phase 11 site📍 Shenzhen Beijing Biotech · Tests: ETB-DualNK-01, Fludarabine, Cyclophosphamide GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201) NCT07871435Phase 1, Phase 26 sites📍 New York📍 Seoul📍 Seoul GI Innovation, Inc. · Tests: GI-102, Pasritamig A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors NCT07887971Phase 11 site📍 Miami Aktis Oncology, Inc. · Tests: [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) NCT07244341Phase 129 sites📍 La Jolla📍 Boston📍 Newton Daiichi Sankyo · Tests: Valemetostat, Darolutamide Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC NCT06855277Phase 3106 sites📍 Homewood📍 Tucson📍 Orange Novartis Pharmaceuticals · Tests: AAA817, ARPI, Standard of Care A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer NCT06990880Phase 1, Phase 220 sites📍 Phoenix📍 Denver📍 New Haven GlaxoSmithKline · Tests: GSK5458514 Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624Phase 3288 sites📍 Orange📍 Palo Alto📍 Riverside Merck Sharp & Dohme LLC · Tests: Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors NCT03972657Phase 1, Phase 224 sites📍 Gilbert📍 Phoenix📍 Tucson Regeneron Pharmaceuticals · Tests: REGN5678, Cemiplimab A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer NCT06533644Phase 223 sites📍 Phoenix📍 Tucson📍 Little Rock Syncromune, Inc. · Tests: Partial Oncolysis, SV-102 A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer NCT05125016Phase 1, Phase 214 sites📍 Palo Alto📍 New Haven📍 Louisville Regeneron Pharmaceuticals · Tests: REGN4336, REGN5678 Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients NCT06615752Phase 1, Phase 21 site📍 Los Angeles Charles Drew University of Medicine and Science · Tests: green tea and quercetin + docetaxel, Placebo + docetaxel A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide NCT06844383Phase 28 sites📍 Duarte📍 La Jolla📍 Boston Prostate Cancer Clinical Trials Consortium · Tests: Talazoparib with enzalutamide, Talazoparib Study of AZD0754 in Participants With Metastatic Prostate Cancer NCT06267729Phase 1, Phase 215 sites📍 Duarte📍 Tampa📍 Atlanta AstraZeneca · Tests: AZD0754, AZD2287 Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC NCT06971211Phase 21 site📍 Shenyang Jianbin Bi · Tests: Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and pred…
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy